Therapy of Hyperhomocysteinemia in Hemodialysis Patients: Effects of Folates and N-Acetylcysteine

Journal of Renal Nutrition

Volumn 22, Issue 5, 2012, Pages

  Perna, Alessandra F ^a   Violetti, Eleonora ^a,b   Lanza, Diana ^a   Sepe, Immacolata ^a   Bellinghieri, Guido ^c   Savica, Vincenzo ^d   Santoro, Domenico ^c   Satta, Ersilia ^c   Cirillo, Giovanni ^a   Lupo, Antonio ^e   Abaterusso, Cataldo ^e   Raiola, Ilaria ^a   Raiola, Paolino ^a   Coppola, Salvatore ^f   Di Iorio, Biagio ^g   Tirino, Giuseppina ^a   Cirillo, Massimo ^a   Ingrosso, Diego ^a   De Santo, Natale G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Civic Hospital of Lugano   (Switzerland)

^c UNIVERSITY OF MESSINA   (Italy)

^d Papardo Hospital   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f Piedimonte Matese Hospital   (Italy)

^g Landolfi Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84865394047     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.10.007     Document Type: Article

References (22)

1. Clarke R., Halsey J., Lewington S., et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010, 170:1622-1631.
2. Perna A.F., Ingrosso D., Violetti E., et al. Hyperhomocysteinemia in uremia-a red flag in a disrupted circuit. Semin Dial 2009, 22:351-356.
3. Ingrosso D., Cimmino A., Perna A.F., et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uremia. Lancet 2003, 361:1693-1699.
4. Massy Z.A. Therapy of hyperhomocysteinemia in chronic kidney disease. Semin Nephrol 2006, 26:24-27.
5. Jamison R.L., Hartigan P., Kaufman J.S., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007, 298:1163-1170.
6. Heinz J., Kropf S., Domröse U., et al. B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010, 121:1432-1438.
7. Bostom A.G., Carpenter M.A., Kusek J.W., et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011, 123:1763-1770.
8. Qin X., Huo Y., Langman C.B., et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2010, 6:482-488.
9. Ducloux D., Aboubakr A., Motte G., et al. Hyperhomocysteinaemia therapy in hemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12. Nephrol Dial Transplant 2002, 17:865-870.
10. Ventura P., Panini R., Pasini M.C., Scarpetta G., Salvioli G. N-acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol Res 1999, 40:345-350.
11. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse and endothelial function in patients with end-stage renal failure. Circulation 2004, 1009:369-374.
12. Thaha M., Yogiantoro M., Tomino Y. Intravenous N-acetylcysteine during hemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease. Clin Drug Invest 2004, 26:195-202.
13. Soldini D., Zwahlen H., Gabutti L., Marzo A., Marone C. Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients. Eur J Clin Pharmacol 2005, 60:859-864.
14. Nolin T.D., Ouseph R., Himmelfarb J., McMenamin M.E., Ward R.A. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clin J Am Soc Nephrol 2010, 5:1588-1594.
15. Tepel M., van der Giet M., Statz M., Jankowski J., Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. Circulation 2003, 107:992-995.
16. Friedman A.N., Bostom A.G., Laliberty P., Selhub J., Shemin D. The effects of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis 2003, 41:442-446.
17. Sunder-Plassmann G., Födinger M., Buchmayer H., et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000, 11:1106-1116.
18. Perna A.F., Satta E., Acanfora F., Lombardi C., Ingrosso D., De Santo N.G. Increased plasma protein homocysteinylation in hemodialysis patients. Kidney Int 2006, 69:869-876.
19. Dawson-Saunders B., Trapp R.G. Basic and Clinical Biostatistics 1990, Appleton & Lange, Norwalk, CT, 119.
20. Sengupta S., Chen H., Togawa T., et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 2001, 276:30111-30117.
21. Perna A.F., Ingrosso D., Lombardi C., et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003, 84:S137-S140.
22. Podhradský D., Drobnica L., Kristian P. Reactions of cysteine, its derivatives, glutathione coenzyme A, and dihydrolipoic acid with isothiocyanates. Experientia 1979, 35:154-155.